While we focused solely on the IGFBP3 binding activity in vivo to avoid the additional complexity of VEGF-trap controls, the added anti-angiogenic properties may render BP3-VEGF-trap-Fc even more potent in cancer therapy. The gene discussed is VEGFA; the disease is cancer.